PRESS RELEASE

MolMed presents at the 8th Advanced Therapies Summit together with the main players in the field of advanced therapies in Europe

Up for discussion will be the current clinical and market "momentum" in advanced therapies and the main issues associated to their market access in Europe and in the world.

Milan (Italy), March 14th, 2018 – MolMed S.p.A. (MLDM.MI), a medical biotechnology company focusing on research, development, manufacturing, and clinical validation of Cell & Gene therapies to treat cancer and rare diseases, presents today at the 8th edition of the Advanced Therapies Summit, the ARM[1] forum, held this year in Amsterdam. The conference annually gathers top representatives and stakeholders leading the evolution of the ATMP framework in Europe in the Advanced Therapy Medicinal Product (ATMP) field, with the aim to facilitate discussions and define recommendations on the development of the field in Europe.

This year the agenda includes, inter alia, two core panel discussions: the latest market evolutions, and the main market access issues. Public policy makers leading the ATMP field evolution in Europe, along with members of the advanced therapies industry, will highlight the most important and recent results in potentially transformative advanced therapies, exploring the main challenges met from their discovery to market access.

Luca Alberici, MolMed's Chief Business Officer, will speak during the first plenary session on the *momentum* and recent success achieved by advanced therapies from a clinical and approval standpoint and the opportunities and ways for stakeholders to support the ATMP growth in Europe. Furthermore, Alberici will partake in the discussion on the main themes related to the market access in Europe, and specifically on the "Health Technology Assessment, Pricing and Funding of ATMPs in Germany". MolMed is in fact one of the first companies to have obtained the Conditional Market Approval in Europe, together with the market authorization, and price and reimbursement in Germany and Italy, for its proprietary advanced therapy Zalmoxis®.

Besides MolMed, some of the main leading world players from the biopharma and regenerative field will join the forum.

A detailed agenda of the event is available at the link https://alliancerm.org/event/atsummit

About MolMed

[1] Alliance for Regenerative Medicine, one of the most authoritative world organization devoted to the support of regenerative medicine and other potentially lifesaving Cell & Gene therapies.

MolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis® received Orphan Drug Designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy at the end of 2017 and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the company is developing a therapy based on Chimeric Antigen Receptor (CAR), specifically the CAR-T CD44v6, an immune gene therapy project, currently in advanced preclinical development, potentially effective for hematological malignancies and several solid epithelial tumors. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, a GSK gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the framework of innovative anticancer therapies, MolMed's pipeline also includes NGR-hTNF, a therapeutic agent for solid tumors investigated in a broad clinical program, involving more than 1,000 treated patients. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

For further information:

Ilaria Candotti

Investor Relations & Communication Manager
MolMed S.p.A.
phone: +39 02 21277.205
fax: +39 02 21277.325
e-mail: investor.relations@molmed.com

Marcella Ruggiero

Press agent
SEC Relazioni Pubbliche e Istituzionali s.r.l.
phone: +39 02 6249991
mobile +39 335 214241
e-mail: ruggiero@secrp.com